Published in Drug Law Weekly, March 22nd, 2005
Total revenues for the fourth quarter and full year ended December 31, 2004, were $2.3 million and $14.1 million, respectively, as compared to $9.0 million in the fourth quarter of 2003 and $41.2 million for the year ending December 31, 2003.
The company's net loss for the fourth quarter and full year 2004 was $37.5 million, or $0.47 per share and $164.8 million, or $2.21 per share, respectively.
The fourth quarter 2004 loss includes a charge of $12.1 million to adjust the carrying value of previously capitalized costs associated with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.